Top

Published in:

01-12-2010 | Original Article

Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer

Authors: Celia Prior, Francisco Guillen-Grima, Jose E. Robles, David Rosell, Jose M. Fernandez-Montero, Xabier Agirre, Raúl Catena, Alfonso Calvo

Published in: World Journal of Urology | Issue 6/2010

Abstract

Objective

To measure a combination of novel molecular biomarkers in urine/blood samples of consecutive patients referring lower urinary tract symptoms (LUTS) not previously diagnosed, to improve prostate cancer diagnosis.

Methods

Serum and urine samples from 113 men who went consecutively to the Department of Urology of our Institution. Biomarkers analyzed were AMACR and MMP-2 levels, and GSTP1/RASSF1A methylation status, in addition to PSA levels. Sensitivity, specificity, area under the ROC (AUROC) curves, and discriminant function analysis were assessed to determine the diagnostic potential of each variable alone or in combination.

Results

Of the patients, 30.08% had PCa and the remaining ones were tumor free. Areas under the ROC (AUROC) curves were as follows: 0.476 for PSA, 0.532 for AMACR, and 0.706 for MMP-2. Sensitivity and specificity for methylation status were 53.3 and 45.9%, respectively. The combination of these biomarkers resulted in an AUROC curve of 0.788, which significantly outperformed AUROC curves for PSA (P = 0.0033) and AMACR (P = 0.0375). Sensitivity, specificity, positive and negative predictive values for the combination of biomarkers were 57.1, 96.6, 88.9, and 82.4%, respectively.

Conclusion

We conclude that analysis of this biomarker combination in body fluids improves very significantly the diagnosis of PCa compared to the PSA test.

Lilja H, Ulmert D, Vickers AJ (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8(4):268–278CrossRefPubMed

Loeb S, Catalona WJ (2008) What to do with an abnormal PSA test. Oncologist 13(3):299–305CrossRefPubMed

Thompson IM, Chi C, Ankerst DP et al (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98(16):1128–1133CrossRefPubMed

Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350(22):2239–2246CrossRefPubMed

Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J (2005) Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165(16):1857–1861CrossRefPubMed

Ulmert D, Serio AM, O’Brien MF et al (2008) Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 26(6):835–841CrossRefPubMed

Djavan B, Margreiter M (2007) Biopsy standards for detection of prostate cancer. World J Urol 25(1):11–17CrossRefPubMed

Laxman B, Morris DS, Yu J et al (2008) A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68(3):645–649CrossRefPubMed

Sreekumar A, Laxman B, Rhodes DR et al (2004) Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96(11):834–843CrossRefPubMed

10.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18(5):1135–1149PubMed

11.

Stearns ME, Stearns M (1996) Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 8(2):63–67PubMed

12.

Costa VL, Henrique R, Jeronimo C (2007) Epigenetic markers for molecular detection of prostate cancer. Dis Markers 23(1–2):31–41PubMed

13.

Hoque MO, Topaloglu O, Begum S et al (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23(27):6569–6575CrossRefPubMed

14.

Jeronimo C, Usadel H, Henrique R et al (2002) Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60(6):1131–1135CrossRefPubMed

15.

Bensalah K, Lotan Y, Karam JA, Shariat SF (2008) New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11(2):112–120CrossRefPubMed

16.

Shah RB, Mehra R, Chinnaiyan AM et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64(24):9209–9216CrossRefPubMed

17.

Tinzl M, Marberger M, Horvath S, Chypre C (2004) DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol 46(2):182–186 (discussion 7)CrossRefPubMed

18.

Henrique R, Jeronimo C (2004) Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 46(5):660–669 (discussion 9)CrossRefPubMed

19.

Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana JS (2006) Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 6:254CrossRefPubMed

20.

Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D (2004) Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10(16):5518–5522CrossRefPubMed

21.

Morgia G, Falsaperla M, Malaponte G et al (2005) Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33(1):44–50CrossRefPubMed

Title: Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer
Authors: Celia Prior
Francisco Guillen-Grima
Jose E. Robles
David Rosell
Jose M. Fernandez-Montero
Xabier Agirre
Raúl Catena
Alfonso Calvo
Publication date: 01-12-2010
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 6/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-010-0583-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2010

Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the stephenson nomogram

Extraperitoneal laparo-endoscopic single-site radical prostatectomy: first experience

Has blood volume an impact on serum PSA levels?

Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging

Significance of postbiopsy hemorrhage observed on preoperative magnetic resonance imaging in performing robot-assisted laparoscopic radical prostatectomy

Clinical impact of intraoperative frozen sections during nerve-sparing radical prostatectomy